Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency
22 Aug 2019
FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA
Mundipharma announces exclusive license and supply agreement with Prestige Biopharma for Tuznue® (HD201)
2 Jul 2019
FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY
Invokana® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
11 Jun 2019
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY
